Skip to main content

Table 9 Multivariate regression analysis of potential DDIs

From: A comprehensive evaluation of potentially significant drug-drug, drug-herb, and drug-food interactions among cancer patients receiving anticancer drugs

 

Model

Unstandardized Coefficients

Standardized Coefficients

t

p-value*

95.0% Confidence Interval for B

Collinearity Statistics

  

B

Std. Error

Beta

  

Lower Bound

Upper Bound

VIF

1

(Constant)

.701

.546

 

1.283

0.200

   
 

Age

.803

.421

.090

1.907

0.057

.237

.106

.081

 

Duration

-.712

.260

-.118

-2.737

0.007

-.157

-.151

-.117

 

Comorbidities

1.672

.280

.309

5.971

 < 0.001

.489

.317

.255

 

All drugs used

3.320

.431

.383

7.710

 < 0.001

.545

.396

.329

 

Anticancer treatment

.449

.411

.051

1.094

0.275

.130

.061

.047

 

Number of reported symptoms

.107

.054

.086

1.967

0.050

.106

.109

.084

  1. The bold P-value indicates significant differences